These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. NS5806 partially restores action potential duration but fails to ameliorate calcium transient dysfunction in a computational model of canine heart failure. Maleckar MM; Lines GT; Koivumäki JT; Cordeiro JM; Calloe K Europace; 2014 Nov; 16 Suppl 4():iv46-iv55. PubMed ID: 25362170 [TBL] [Abstract][Full Text] [Related]
25. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure. Pouleur H; Hanet C; Schröder E; Col J; Van Mechelen H; Etienne J; Rousseau MF J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S18-22. PubMed ID: 2478787 [TBL] [Abstract][Full Text] [Related]
26. Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy. Joho S; Asanoi H; Ishizaka S; Kameyama T; Inoue H J Card Fail; 2002 Dec; 8(6):423-30. PubMed ID: 12528096 [TBL] [Abstract][Full Text] [Related]
27. Polydatin modulates Ca(2+) handling, excitation-contraction coupling and β-adrenergic signaling in rat ventricular myocytes. Deng J; Liu W; Wang Y; Dong M; Zheng M; Liu J J Mol Cell Cardiol; 2012 Nov; 53(5):646-56. PubMed ID: 22921781 [TBL] [Abstract][Full Text] [Related]
28. Calcium-calmodulin kinase II mediates digitalis-induced arrhythmias. Gonano LA; Sepúlveda M; Rico Y; Kaetzel M; Valverde CA; Dedman J; Mattiazzi A; Vila Petroff M Circ Arrhythm Electrophysiol; 2011 Dec; 4(6):947-57. PubMed ID: 22009705 [TBL] [Abstract][Full Text] [Related]
29. Inotropic response of cardiac ventricular myocytes to beta-adrenergic stimulation with isoproterenol exhibits diurnal variation: involvement of nitric oxide. Collins HE; Rodrigo GC Circ Res; 2010 Apr; 106(7):1244-52. PubMed ID: 20167926 [TBL] [Abstract][Full Text] [Related]
30. Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure. Kawano H; Arakawa S; Satoh O; Matsumoto Y; Hayano M; Nakatomi D; Yamasa T; Maemura K Geriatr Gerontol Int; 2014 Jan; 14(1):109-14. PubMed ID: 23581555 [TBL] [Abstract][Full Text] [Related]
31. Sex-dependent alterations of Ca2+ cycling in human cardiac hypertrophy and heart failure. Fischer TH; Herting J; Eiringhaus J; Pabel S; Hartmann NH; Ellenberger D; Friedrich M; Renner A; Gummert J; Maier LS; Zabel M; Hasenfuss G; Sossalla S Europace; 2016 Sep; 18(9):1440-8. PubMed ID: 26493982 [TBL] [Abstract][Full Text] [Related]
32. Role of RyR2 phosphorylation at S2814 during heart failure progression. Respress JL; van Oort RJ; Li N; Rolim N; Dixit SS; deAlmeida A; Voigt N; Lawrence WS; Skapura DG; Skårdal K; Wisløff U; Wieland T; Ai X; Pogwizd SM; Dobrev D; Wehrens XH Circ Res; 2012 May; 110(11):1474-83. PubMed ID: 22511749 [TBL] [Abstract][Full Text] [Related]
33. Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure. Wilson K; Guggilam A; West TA; Zhang X; Trask AJ; Cismowski MJ; de Tombe P; Sadayappan S; Lucchesi PA Am J Physiol Heart Circ Physiol; 2014 Dec; 307(11):H1605-17. PubMed ID: 25260618 [TBL] [Abstract][Full Text] [Related]
34. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042 [TBL] [Abstract][Full Text] [Related]
35. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. Sossalla S; Wagner S; Rasenack EC; Ruff H; Weber SL; Schöndube FA; Tirilomis T; Tenderich G; Hasenfuss G; Belardinelli L; Maier LS J Mol Cell Cardiol; 2008 Jul; 45(1):32-43. PubMed ID: 18439620 [TBL] [Abstract][Full Text] [Related]
36. Dynamin-2 mediates heart failure by modulating Ca2+ -dependent cardiomyocyte apoptosis. Li J; Zhang DS; Ye JC; Li CM; Qi M; Liang DD; Xu XR; Xu L; Liu Y; Zhang H; Zhang YY; Deng FF; Feng J; Shi D; Chen JJ; Li L; Chen G; Sun YF; Peng LY; Chen YH Int J Cardiol; 2013 Oct; 168(3):2109-19. PubMed ID: 23410488 [TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure. Baumann G; Ningel K; Permanetter B J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S23-30. PubMed ID: 2478788 [TBL] [Abstract][Full Text] [Related]
38. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Hagemeijer F Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722 [TBL] [Abstract][Full Text] [Related]
39. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. Ohte N; Cheng CP; Suzuki M; Little WC J Pharmacol Exp Ther; 1997 Jul; 282(1):23-31. PubMed ID: 9223536 [TBL] [Abstract][Full Text] [Related]
40. ORM-3819 promotes cardiac contractility through Ca(2+) sensitization in combination with selective PDE III inhibition, a novel approach to inotropy. Nagy L; Pollesello P; Haikala H; Végh Á; Sorsa T; Levijoki J; Szilágyi S; Édes I; Tóth A; Papp Z; Papp JG Eur J Pharmacol; 2016 Mar; 775():120-9. PubMed ID: 26872993 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]